CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This ...

Tempus AI (TEM), announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for ...

Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% ...